secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-119064
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q3 net loss $8.5M; cash $5.4M; Phase 2 starts for COVID and flu drugs in 2025
--------------------------------------------------------------------------------

- Net loss of $8.5M ($8.81 per share) vs $4.7M loss in Q3 2023; R&D expense $5.1M, G&A $3.5M.
- Cash and short-term investments $5.4M as of Sept 30, down from $20.8M at Dec 31, 2023.
- Ratutrelvir (COVID) Phase 1 data supports once-daily dosing without ritonavir; Phase 2 targeted in 2025.
- Tivoxavir marboxil (flu) Phase 1 data supports single-dose treatment; Phase 2 targeted in 2025.
- Luba Greenwood appointed to board of directors; shares outstanding 3,025,554 after 25:1 reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/0001104659-24-119064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/tm2428509d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer